Cell shape recognition technology
Research type
Research Study
Full title
The Development of Bioimprinting Technology for the Removal of Leukaemia Cells from Patient Blood Samples.
IRAS ID
214660
Contact name
David Allsup
Contact email
Sponsor organisation
Hull and East Yorkshire NHS Trust
Duration of Study in the UK
2 years, 11 months, 31 days
Research summary
There are around 2,900 cases of acute myeloid leukaemia (AML) diagnosed nationally each year with this disease being the ninth most common cause of cancer death in the UK. New treatments are desperately required for patients with acute leukaemia due to the severe side effects from conventional treatments. Our aim is to develop a less toxic, effective treatment for patients with AML. Professor Paunov and Dr Madden in the University of Hull have used a novel method that recognises the shape of cells and uses this recognition to selectively kill the cells. In this project we aim to apply a similar technology (called bioimprinting) to remove the cancerous cells from the blood of AML patients.
The aim of this project is to obtain blood samples from patients with AML and another type of leukaemia called chronic lymphocytic leukaemia (CLL) for use in a laboratory setting to further develop bioimprinting as a way of removing leukaemia cells from blood samples. At this point the project is at a developmental stage and not at the point at which it could be applied clinically.REC name
London - West London & GTAC Research Ethics Committee
REC reference
16/LO/1948
Date of REC Opinion
8 Nov 2016
REC opinion
Further Information Favourable Opinion